CPDD President’s Column

LINDA Porrino, Ph.D.
President

I want to take this opportunity to wish each and every one of you a very happy New Year. I hope that all of you have had very happy holidays and the new year and the new decade find you healthy and happy. CPDD begins the 20-teens in excellent shape thanks to the hard work of our Executive Office headed by Marty Adler, our Treasurer, Stephen Holtzman, and our Board of Directors. There are a few things that I want to bring to your attention. Our elections for new members of the Board of Directors and President-elect will be held this month. We will once again be using email ballots that make it easy and convenient to cast your votes. So be on the lookout for an email ballot and please take the time to participate in the elections. There is still some time for nominations for the Eddy, Fischman, Morrison, Mentorship and Cochini Young Investigator Awards. The deadline is February 1, 2010. Information about each award, the qualifications and a list of past winners is on the CPDD website.

Planning for the June meeting is going well. The Program Committee has put together an exciting list of symposia and workshops this year. They cover a broad range of topics, from genetics of nicotine dependence and treatment, to HIV treatment in the criminal justice system, to drug development for addiction treatment. Check out the full list on the website [and on pages 3, 7 and 10 of this newsletter]. We also had a record number of workshop proposals this year. So, the program will be a full one with many themes and issues represented. I look forward to seeing you all in Scottsdale.

The past year has seen increasingly militant activity of a small group of individuals opposed to the use of animals in research. The firebombing of a car parked in the driveway of David Jentsch’s home in Los Angeles is just one example. Dr. Jentsch is a Professor at the Brain Research Institute at UCLA who studies the impact of drugs on genetics and neurochemistry of cognitive and executive functions. These kinds of attacks have sparked the formation of Speaking of Research which seeks to provide information about the importance of animal research in medical science (http://speakingofresearch.com). Speaking of Research, along with organizations such as Americans for Medical Progress (http://www.amprogress.org/), have helped to support scientists and their research and to combat these activities. CPDD continues to support the efforts of these and other organizations that advocate for research. Check out their websites to learn about their activities and for information about how you can help.

At this year’s CPDD meeting we will have a forum entitled, “Animals in Research Forum: What Can I Do and How Can We Work with Others to Build Support for Animal Research?” I hope

Continued on page 2
many of you will attend to hear how we can better educate the public and our colleagues about the value, need and importance of animal research and what strategies we can use to combat the small segment of activists bent on the use of violence against scientists who use lab animals in their research.

In my last column I talked about the deliberations of the Scientific Management Review Board (SMRB) considering the potential merger of NIDA and NIAAA. To address the question of a merger, a working group called Substance Use, Abuse and Addiction (SUAA) has been appointed. It is chaired by William Roper from the University of North Carolina. Other members include Josephine Briggs from the National Center for Complementary and Alternative Medicine, Richard Hodes from the National Institute on Aging, Deborah Powell of the University of Minnesota Medical School, Griffin Rodgers of the National Institute of Diabetes and Digestive and Kidney Diseases, Lawrence Tabak of the National Institute of Dental and Craniofacial Research, Eugene Washington from the University of California, San Francisco and Huda Zoghbi from Baylor College of Medicine.

The SUAA has met twice (on September 23, 2009 and October 14, 2009), with the first meeting dedicated to public health issues and the science of substance abuse. I had the privilege of providing testimony at this meeting along with others representing the views of NIDA and NIAAA. As President of CPDD, I focused on the breadth and inclusiveness of our organization and the value of an integrated approach to substance abuse research, ranging from molecular and genetics research, to systems research, to treatment and prevention studies, that is presented at our meetings, as well as the many different abused substances that are covered. I was impressed by the very deliberate nature of the process with ample opportunity to consider many, many points of view and the benefits and concerns about the potential merger. The SUAA members asked penetrating questions and appeared to have no bias one way or another. The Chair stressed in his opening statement that this potential merger was not being considered as a cost-cutting measure. He also tried to dispel the rumor that the merger is being considered to enable the formation of another institute within the NIH. However, the number of NIH institutes is currently capped by law at 27, and Dr. Roper was clear that this was not part of his understanding. The second round of testimony in October included members of the academic community, industry representatives, and individuals from the justice system. Future SUAA meetings will hear from former institute directors and about the lessons learned from previous government reorganizations and mergers.

The full SMRB met in November. At that time Dr. Roper summarized the findings of the SUAA so far to the full board. He stated that advocates for a merger have pointed out that: 1) the science would benefit from synergy of commonalities that indicate common mechanisms and risk factors; 2) there exists a high prevalence of co-morbidity; 3) segregation of disciplines produces public health gaps; and 4) reorganization would create synergy of inquiry and flexibility for cross-training for treatment and research. He summarized the arguments...
CPDD Meeting 2010: Scottsdale

Full Symposia:

Effective Treatment Approaches for Addressing Addiction in HIV and Criminal Justice Populations
   Timothy P. Condon, Chair, and Redonna Chandler, Co-Chair

The Role of GABA in Drug Abuse
   Diana Dow-Edwards, Chair

Hair of the Dog: Agonists for Stimulant Dependence
   John Grabowski, Chair, and David Herin, Co-Chair

Gender Differences in Response to Social Stress: Parallels from Cocaine and Alcohol Research in Human and Non-Human Primates
   Colleen A. Hanlon, Chair, and Cora Lee Wetherington, Co-Chair

Preclinical to Clinical Abuse Liability Assessment: Current Challenges in Industry Practices
   Mary Jeanne Kallman, Chair, and David Compton, Co-Chair

A Comprehensive Examination of the Use and Impact of Cannabis: From Brain Effects to Epidemiological Impact Across The World
   Flavio Pechansky, Chair, and Alison Ritter, Co-Chair

Translating the Genetics and Neurochemistry of Nicotine Dependence to Drug Development
   Linda Porrino, Chair, and Joni L. Rutter, Co-Chair

Screening and Brief Intervention for Drug Use: Does It Work? Will It Work in the Real World?
   Richard Saitz, Chair, and Richard Denisco, Co-Chair

The Role of the Hypocretin/Orexin System in Addiction: Current Status and Rationale as a Drug Discovery Target
   David Shurtleff, Chair, and Sari Izenwasser, Co-Chair

Novel Kappa Opioids: From Design to Function
   Ellen Unterwald, Chair, and Eduardo Butelman, Co-Chair

Award Deadlines
Marian W. Fischman Award
Nathan B. Eddy Award
Joseph Cochin Award
Mentorship Award
J. Michael Morrison Award
February 1, 2010

Visit the CPDD web site for award description and information about nominations. http://www.cpdd.org
Meeting Highlights – The 2009 Nathan B. Eddy Award

The Nathan B. Eddy Memorial Award was established in memory of one of the pioneers in the field of drug dependence following his death in 1973. The award acknowledges outstanding research efforts that have advanced our knowledge of drug dependence.

2009 Awardee:
Robert L. Balster, Ph.D.

Dr. Robert L. Balster, a native of Minnesota, received his PhD in Psychology from the University of Houston and did post-doctoral training at the University of Chicago under the direction of Charles R. Schuster. Currently, he is Director of the Institute for Drug and Alcohol Studies, Luther A. Butler Professor of Pharmacology and Toxicology, and Research Professor of Psychology and Psychiatry at Virginia Commonwealth University, Medical College of Virginia campus in Richmond. He is the Editor-in-Chief of Drug and Alcohol Dependence and President-elect of the International Society of Addiction Journal Editors. Dr. Balster is the Coordinator for the VCU site for the U.S. State Department/NIDA Humphrey Fellowship Program in Substance Abuse Prevention, Treatment and Policy and a co-founder and co-director of the International Programme in Addiction Studies, an online master’s degree program. He is a Past-President of the CPDD and recipient of the 2000 CPDD Mentorship Award. Previous appointments also include being a member of the WHO Expert Advisory Panel on Drug Dependence, Chair of the Drug Abuse Clinical and Behavior Study Section at the National Institute on Drug Abuse (NIDA), Chair of the FDA Drug Abuse Advisory Committee, and Chair of the Board of Scientific Affairs of the American Psychological Association. Dr. Balster has authored more than 270 papers in scientific journals, 46 book chapters, and edited two books. The principal areas of Dr. Balster’s research include behavioral pharmacology, drug abuse potential assessment, inhalant abuse and regulatory policy. His research has been continuously funded by the NIH since 1976.

Introduction by Louis Harris, Ph.D.

It gives me great pleasure to introduce Dr. Robert L. Balster, who has been selected as the 2009 recipient of the College on Problems of Drug Dependence (CPDD) Nathan B. Eddy Memorial Award, the most prestigious award in the field of substance abuse research. The award “acknowledges outstanding research efforts that have advanced our knowledge of drug dependence.” Dr. Balster certainly merits its receipt. Born in St. Cloud, Minnesota on October 12, 1944, he received his B.A. degree in Psychology from the University of Minnesota in 1966. This was followed by a Ph.D. from the University of Houston under the direction of Bob Harris in 1970. In that year, he joined Bob Schuster at the University of Chicago for a very productive fellowship. Following one year as an Assistant Professor at Duke University, he joined us in the Department of Pharmacology and Toxicology at MCV/VCU in 1973, where he rose through the ranks to Professor in 1984. In 1997, he founded and became director of our Institute for Drug and Alcohol Studies, an integral part of VCU which has been highly ranked nationally and internationally for its substance abuse program. Dr. Balster has been and continues to be a highly productive research scientist whose work is characterized by utilizing the latest advances in
behavioral sciences to explore questions of pharmacological importance. He played a very important role in the development of two laboratory models that are widely used in drug abuse research. These are the voluntary self-administration of drugs as a model of the euphorogenic effects of drugs, and the first use of operant behavior to study the ability of animals to detect drug injections, a technique which has come to be referred to as drug discrimination. Mention should also be made of his important contributions to the fields of phencyclidine research and inhalant abuse. To date, he has authored nearly 300 articles in scientific journals and books and co-edited two important volumes on the latest advances in his area of research. Dr. Balster is a superb teacher and mentor. He has educated a great many individuals who have gone on to become independent scientists and who have made very significant contributions in their own laboratories. Dr. Balster was the first person to receive the coveted Mentor Award from CPDD and later the NIDA International Award for Excellence in Mentoring. The nomination for this award was the sole effort of his many trainees. Two years ago, Bob was the recipient of the Brady-Schuster Award from the American Psychological Association, another indication of the appreciation of the leaders in the field for the work of this superb scientist. More recently, he and Charles O’Keeffe have secured the Humphrey Scholars program at VCU and initiated a unique Masters degree program in substance abuse studies with King College in London and the University Adelaide in Australia.

Perhaps the best evidence for the excellence of Dr. Balster’s overall contributions to research comes from his visibility within the research community. He has served as Chair of The FDA’s Drug Abuse Advisory Committee and as a Member of The World Health Organization Expert Advisory Panel on Drug Dependence from 1995 to 2003. Bob is one of the few people to be asked to chair a NIDA study section for four years. He is a Past-President of the Division of Psychopharmacology and Substance Abuse of the American Psychological Association and of the College on Problems of Drug Dependence. He is a Fellow of the American College of Neuropsychopharmacology. He is on the Editorial Boards of seven scientific journals, including the most prestigious ones in his area of research. One of his many contributions in recent years has been his outstanding work as Editor-in-Chief of the journal Drug and Alcohol Dependence. The journal has enjoyed considerable growth in quality and size during his tenure as editor and he has implemented a number of new presentations in the journal, which has increased its appeal to the readership. Dr. Balster also serves on the Board of Scientific Affairs of the American Psychological Association. Finally, he received VCU’s Faculty Award for Excellence for teaching, research and service. On a more personal note, Bob is a highly intelligent, dedicated, caring person, and a gourmet and connoisseur of wine. His broad interests qualify him as a “Renaissance Man.” Along with his wife, Sam, and daughter, Sarah, they represent an ideal academic family.

Acceptance Remarks by Dr. Balster

In 1973, the year of Nathan Eddy’s death, I gave my first-ever scientific presentation at a national scientific conference at the CPDD Meeting. As intimidated as I was by all of the assembled expertise in drug abuse research that was in the audience, it never occurred to me that I would be standing before the College these many years later receiving the Nathan B. Eddy Award. To be included among the list of previous Award winners is truly an honor. I consider the CPDD to have been critical to my career development and so am
against as: 1) reorganization would create research gaps, especially with respect to unique factors underlying alcohol abuse and the multiple organ targets of alcohol; 2) contextual and cultural differences warrant separate research efforts; 3) lack of evidence that a merger would improve treatment; and 4) current organization mirrors professional and scientific associations. Dr Roper also pointed out that there are many possible models for their recommendations ranging from continuation of the status quo, a single council above both institutes, mandating joint initiatives; clustering of some functions, or a complete merger. You can see a videocast of his full comments at http://smrb.od.nih.gov/meetings.asp. There are also videocasts of the SUAA meetings. I urge you to take a look and become informed about the possibilities. One thing became clear to me in providing testimony and watching and reading about the merger, and that is that this is a very contentious issue. There has been a great deal of polarization within both communities. It has also cost a tremendous amount of time, money and energy. We can hope that there is some resolution soon and that we can all get back to the business of research on substance abuse soon.

Again, I hope that all have a happy and prosperous new year and I want to thank all of the members of the Executive Office for all of their hard work. Thanks Marty, Ellen, Neico, Connie, Rochelle, and Toby. Thanks also to all of you for all that you do to make CPDD an effective and welcoming organization.

Nathan B. Eddy B. Award continued from page 5

especially pleased to receive this Award. In my remarks to the College, I stressed the importance to me of integrating teaching and mentoring with research and service. I have been blessed by having many pre- and post-doctoral fellows who have been my collaborators in almost all of my research. I also have many colleagues and staff with whom I have worked and am working now. I thank them all for being such an important part of my life. I thank Lou Harris, Bill Dewey, Ian Stolerman and Chris-Ellyn Johanson who nominated me for the award. I thank the Award Committee for selecting me from such a strong list of worthy recipients, and I thank the College for being the important force that it is for excellence in science and the translation of science into practice and policy. I hope this is just a mid-career award and that I can continue to make contributions to the field.

See you in Scottsdale!
CPDD Meeting 2010: Scottsdale

Mini Symposia:

The Role of Dopamine D3 Receptors in Cocaine Abuse
Jane B. Acri, Chair

Medications Development for the Treatment of Substance Dependence: Status of Advanced Projects
David McCann, Chair

Methamphetamine Addiction: From Molecular Mechanisms to Treatment
John Mendelson, Chair, and Jean Lud Cadet, Co-Chair

Current Issues Surrounding Chronic Pain among Individuals with a Substance Use Disorder
Benjamin J. Morasco, Chair

NICO-TEEN: Adolescence Is a Period of Enhanced Vulnerability to Tobacco Abuse
Laura O’Dell, Chair, and Janet Neisewander, Co-Chair

New Pathways to Future Addiction Therapy
John Satterlee, Chair

Community-Based Responses to Increasing Opioid Overdose Deaths: State of Research and Practice
Alexander Y. Walley, Chair, and Alex Kral, Co-Chair

The Multi-Site NIDA Clinical Trials Network Prescription Opioid Addiction Treatment Study: Outcomes and Implications
Roger D. Weiss, Chair, and Petra Jacobs, Co-Chair

Animal Forum:

Animals in Research Forum: What Can I Do and How Can We Work with Others to Build Support for Animal Research?
Nancy A. Ator, Chair, and Shane A. Perrine, Co-Chair

Drug Discrimination and Self-Administration Databases Combined

They are now available at: www.drugrefs.org

The former drug discrimination database can still be accessed at www.dd-database.org but it is not being updated.
Meeting Highlights – The 2009 CPDD/NIDA Media Award

This award is given to a member of the media who has made major contributions to the public understanding of scientific issues concerning drug use disorders.

2009 Awardee:
Nancy D. Campbell, Ph.D.

Nancy D. Campbell is an Associate Professor in the Department of Science and Technology Studies at Rensselaer Polytechnic Institute in Troy, New York. Her most recent book, The Narcotic Farm: The Rise and Fall of America’s First Prison for Drug Addicts (Harry N. Abrams, Inc., 2008, co-authored with JP Olsen and Luke Walden), is a visual history of the federal drug treatment hospital in Lexington, Kentucky. Her book-length, scholarly history of the science conducted by the Addiction Research Center (now the intramural research program of the National Institute on Drug Abuse) is titled Discovering Addiction: The Science and Politics of Substance Abuse Research (University of Michigan Press, 2007). Her first book was Using Women: Gender, Drug Policy, and Social Justice (Routledge, 2000). With Joseph Spillane, she created the Oral History of Substance Abuse Research Project, which was funded by the National Science Foundation, the College on Problems of Drug Dependence, and the University of Michigan Substance Abuse Research Center (http://sitemaker.umich.edu/substance_abuse.history/home). Campbell was awarded her doctoral degree in 1995 from the History of Consciousness Program at the University of California at Santa Cruz for a dissertation titled, "Cold War Compulsions: U.S. Drug Policy, Science, and Culture."

Introduction by Marc Kaufman, Ph.D.

On behalf of the CPDD Media Relations Committee, I’m very pleased to be here this morning to participate in this joint presentation of the 2009 Media Award by CPDD and NIDA to Dr. Nancy Campbell, historian and author of a number of multimedia works about substance abuse, its treatment, and its societal impact. Dr. Campbell is an Associate Professor in the Department of Science and Technology Studies at Rensselaer Polytechnic Institute in Troy, New York. She received her doctoral degree in 1995 from the History of Consciousness Program at the University of California at Santa Cruz. She is being recognized today for a number of contributions including her book-length, scholarly history of the science conducted by the Addiction Research Center, now known as the NIDA intramural research program. The book is entitled Discovering Addiction: The Science and Politics of Substance Abuse Research. With Joseph Spillane, she created an online resource entitled Oral History of Substance Abuse Research Project, which was funded by CPDD, the National Science Foundation, and by the University of Michigan Substance Abuse Research Center. Her most recent book, The Narcotic Farm: The Rise and Fall of America’s First Prison for Drug Addicts, co-authored with JP Olsen and Luke Walden, is a visual history of the federal drug treatment hospital in Lexington, Kentucky, and accompanied a Public Broadcasting Service television documentary. Dr. Campbell has been interviewed about her work by numerous media outlets including National Public Radio. Please join me in extending a warm welcome and congratulations to Dr. Campbell.

Continued on page 9
abuse research as my own research topic in the history of science. When researching 1950s drug policy for my dissertation, I first realized that there was a small cadre opposing criminalization and arguing for a public health approach. Why were they all from Lexington, Kentucky? What, I wondered, was in the water in Lexington, Kentucky, that people there opposed mandatory minimum sentences leveled in 1951? To argue way back then that addiction was a disease, not a crime? To argue stigma compounded the problems addicts faced before, during, and after treatment? They lost their battle, but I was hooked.

Introducing people to their history is not always easy, steeped as it is in lore and nostalgia, old fights, love affairs, power struggles, and plain old forgetfulness. We do not always speak the same languages, you and I. This award is especially meaningful because of the trust on which it is based. To me this award signals that we have worked across disciplinary divides and intellectual differences to a place of conviviality and respect. Your field will always face the storm of public perceptions and ever-new crises. As you advocate for your science and seek to translate what you do into terms understandable to multiple publics, you face many political challenges as scientists and as citizens. If my work enables more people to understand that, I will have earned this award.

One generalization I can draw from my historical studies is that no knowledge paradigm lasts forever. How we know what we know is forever changing. How “drug problems” are defined today give way to tomorrow’s project to redefine terms, redraw boundaries, and reconstitute knowledge. One relatively constant anchor in this sea of flux has been this organization, the College on Problems

continued from page 8
CPDD Meeting 2010: Scottsdale

Workshops:

Epidemiology and Public Health Research Methods
Jim Anthony, Chair, and Silvia Martins, Co-Chair

New Approaches to Diagnosis in the DSM-V
Wilson M. Compton, Chair, and Charles P. O’Brien, Co-Chair

16th Annual Contingency Management Working Group
Kelly Dunn, Chair, and Kathryn Saulsgiver, Co-Chair

School-Based Systems of Care for Substance Abuse: Student Assistance Programs and Recovery Schools / SASATE Business Meeting
Andrew J. Finch, Chair, and Michael Dennis, Co-Chair

Minimize Liability, Manage Risk, Ensure Patient Safety: Effective Strategies in Outpatient Methadone Treatment
Michael T. Flaherty, Chair, and Trusandra Taylor, Co-Chair

What’s New at NIDA and NIH: Enhancing Peer Review Implementation and More
Mark R. Green, Chair, and Teri Levitin, Co-Chair

Teach Your Parents Well: Teaching and Training Parents Concerned about Their Child’s Drug Use
Kimberly C. Kirby, Chair

Career Development: A Perspective from Junior and Senior Researchers
Gerald McLaughlin, Chair

Comparison of Methadone and Buprenorphine: Results of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) Trial
Ivan D. Montoya, Chair, and Sara Heil, Co-Chair

Effectively Mentoring Trainees from Diverse Backgrounds: Funding Opportunities and Practical Advice
Danielle C. Ompad, Chair, and Liliane Cambraia Windsor, Co-Chair

Academics and Regulated Industries: Perspectives on 21st Century Interactions with Pharmaceutical and Tobacco Companies
Jed Rose, Chair, and George Uhl, Co-Chair

Established and Emerging Approaches to Human Abuse Liability Testing: Is There Room for Improvement?
Edward M. Sellers, Chair

Empirically Supported Treatments and Diverse Populations: Some Examples of Challenges to Adaptation
Anne Helene Skinstad, Chair, and Lonnetta Albright, Co-Chair
Late-Breaking Research Guidelines

A limited number of abstracts will be accepted for presentation as 5-minute talks in a session devoted to important late-breaking, unpublished findings (i.e. after December 1, 2009) at the Annual Meeting. A member of CPDD must be a co-author. Although only 1 abstract of this type is allowed, the author may have submitted another abstract under the regular deadline. Papers can be on any aspect of drug abuse or addiction or on the actions of drugs of abuse. The abstract must contain original research including all prospective and retrospective studies that involve testing a hypothesis by collecting and analyzing data. Abstracts must specify hypothesis, species, number of subjects, procedures, results, statistical analyses, and importance of findings (conclusions). Please note that results must be explicitly described in the abstract, and that abstracts reporting no results will likely be rejected. Abstracts should be 2300 characters or less, including authors.

To have your abstract considered for this special session, e-mail it to ebgeller@temple.edu and sizenwasser@med.miami.edu by April 15, 2010. The subject of your e-mail should be “Late-Breaking Research” and the abstract should be labeled with the last name of the first author.

Upon notification of acceptance of your abstract to the Late-breaking Session, the abstract fee of $50.00 must be sent to the CPDD Executive Office, 3400 North Broad Street, Philadelphia, PA 19140.

2009 CPDD/NIDA Media Award  continued from page 9

of Drug Dependence, or “the Committee,” as it was known in its earliest days. I once encountered a shocked archivist at the National Academies of Science, who assumed this organization ended when her files did in 1977. Many times in your past, “the Committee” has faced an uncertain future. Those most committed to its animating principles rallied to ensure its persistence. I would be remiss not to thank Marty and Toby Adler, Chuck O’Brien, and Sharon Walsh for their behind-the-scenes support.

Telling the story of a multidisciplinary field is overwhelming, and overwhelm is the occupational hazard of historians. In selecting the Department of Pharmacology at the University of Michigan, the Behavioral Pharmacology Research Unit at Hopkins, or the Addiction Research Center, which became the NIDA Intramural Research Program—I run the risk of taking the trees for the forest. CPDD and NIDA have defined a field in which many forests now flourish. So many of you strayed into the forest serendipitously, having no real idea beforehand what riches you were to encounter. You stayed and became part of my story.

The “gifts of a fortuitous environment” have been mine. CPDD has been replete with archival riches and relatively untouched by other seekers. I accept the 2009 Media Award in the spirit of an ongoing quest and look forward to seeing what you all come up with next. Coming to CPDD has also enabled a reconfiguration of my career as I embark upon becoming a historian of the present—thus I hope your doors will remain open to history as-yet unwritten. I thank you for your recognition that I might have a few gifts to offer. Most of all I thank you for taking the gamble of trust.